Mark Joseph Nejmeh
P.O. Box 589
Clifton, New Jersey 07012
Telephone: 732-995-3914
Email: research@warrantwire.com
Plaintiff, self-represented

UNITED STATES DISTRICT COURT
DISTRICT OF NEVADA

MARK JOSEPH NEJMEH,
Plaintiff,
v.
THERIVA BIOLOGICS, INC., STEVEN A. SHALLCROSS, JEFFREY J. KRAWS, JEFFREY WOLF and JOHN MONAHAN,
Defendants.

Case No. 3:26-cv-00705-ART-CSD

INDEX OF EXHIBITS TO DECLARATION OF MARK JOSEPH NEJMEH IN SUPPORT OF REPLY ON ECF NO. 42 (LR IA 10-3(d))

Exhibit	Description	Pages
Reply Ex. 1	U.S. Patent No. 9,290,754, issued March 22, 2016 (excerpts: first page and claim 18)	3
Reply Ex. 2	Theriva Biologics, Inc. Form 8-K filed November 2, 2026, with Exhibit 99.1 and Exhibit 10.1 (first pages)	14
Reply Ex. 3	The Globe and Mail web page on Biossil	3
Reply Ex. 4	BetaKit article on Biossil	5
Reply Ex. 5	Theriva Biologics web page therivabio.com/our-pipeline/, November 7, 2026 (excerpts)	3
Reply Ex. 6	Synthetic Biologics, Inc. Form 10-K filed February 22, 2018 (excerpts)	4
Reply Ex. 7	Synthetic Biologics, Inc. Form 10-Q filed November 10, 2020 (excerpts)	3
Reply Ex. 8	Synthetic Biologics, Inc. prospectus supplement filed February 19, 2021 (excerpts)	3

Reply Ex. 9	Form 10-K filed March 16, 2022 and Forms 10-Q filed in 2022, showing period-end cash (excerpts)	10
Reply Ex. 10	Synthetic Biologics, Inc. Form 8-K filed December 14, 2021, with Exhibit 99.1 (excerpts)	4
Reply Ex. 11	Theriva Biologics, Inc. Form 10-Q for the quarter ended June 30, 2026 (excerpts)	5
Reply Ex. 12	Theriva Biologics, Inc. Form 8-K filed August 11, 2026, Exhibit 99.1 (first page)	2
Reply Ex. 13	Heat Biologics, NightHawk Biosciences and Scorpius Holdings Forms 8-K (excerpts)	9
Reply Ex. 14	NYSE American Form 25-NSE notice for Scorpius Holdings, Inc. and Scorpius Form 8-K (excerpts)	4
Reply Ex. 15	Theriva Biologics, Inc. proxy corrections, 2021 and 2023 (excerpts)	7
Reply Ex. 16	Biossil asset purchases disclosed by Galera, GlycoMimetics, Inventiva and Summit (excerpts)	13
Reply Ex. 17	Theriva proxy statement filed June 29, 2026 (excerpts) and Ikarian Capital filings on Kazia Therapeutics and Theriva Biologics (excerpts)	7
Reply Ex. 18	Daily trading prices and volume of Theriva Biologics, Inc. (TOVX), October 5 to 13, 2026	2
Reply Ex. 19	Theriva Biologics, Inc. Form 10-K filed March 12, 2026 (excerpts)	4